Publication:
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.

dc.contributor.authorBento, Leyre
dc.contributor.authorBastida, José María
dc.contributor.authorGarcía-Cadenas, Irene
dc.contributor.authorGarcía-Torres, Estefania
dc.contributor.authorRivera, Daniel
dc.contributor.authorBosch-Vilaseca, Anna
dc.contributor.authorDe Miguel, Carlos
dc.contributor.authorMartínez-Muñoz, María Esther
dc.contributor.authorFernández-Avilés, Francesc
dc.contributor.authorRoldán, Elisa
dc.contributor.authorChinea, Anabelle
dc.contributor.authorYáñez, Lucrecia
dc.contributor.authorZudaire, Teresa
dc.contributor.authorVaz, Carlos Pinho
dc.contributor.authorEspigado, Ildefonso
dc.contributor.authorLópez, Javier
dc.contributor.authorValcárcel, David
dc.contributor.authorDuarte, Rafael
dc.contributor.authorCabrera, Rafael
dc.contributor.authorHerrera, Concepción
dc.contributor.authorGonzález-Porras, José Ramón
dc.contributor.authorGutiérrez, Antonio
dc.contributor.authorSolano, Carlos
dc.contributor.authorSampol, Antonia
dc.contributor.authorGrupo Español de Trasplante Hematopoyético (GETH)
dc.date.accessioned2023-01-25T13:34:19Z
dc.date.available2023-01-25T13:34:19Z
dc.date.issued2019-05-29
dc.description.abstractPersistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), and some studies with very small numbers of cases have reported their potential efficacy in the allo-SCT setting. The present retrospective study evaluated the safety and efficacy of TPO-RAs in 86 patients with persistent thrombocytopenia after allo-HSCT. Sixteen patients (19%) had isolated thrombocytopenia (PT), and 71 (82%) had secondary failure of platelet recovery (SFPR). TPO-RA therapy was started at a median of 127 days (range, 27 to 1177 days) after allo-SCT. The median initial and maximum administered doses were 50 mg/day (range, 25 to 150 mg/day) and 75 mg/day (range, 25 to 150 mg/day), respectively, for eltrombopag and 1 µg/kg (range, 1 to 7 µg/kg) and 5 µg/kg (range, 1 to 10 µg/kg), respectively, for romiplostin. The median platelet count before initiation of TPO-RA therapy was 14,000/µL (range, 1000 to 57,000/µL). Platelet recovery to ≥50,000/µL without transfusion support was achieved in 72% of patients at a median time of 66 days (range, 2 to 247 days). Eighty-one percent of the patients had a decreased number of megakaryocytes before treatment, showing a slower response to therapy (P = .011). The median duration of treatment was 62 days (range, 7 to 700 days). Grade 3-4 adverse events (hepatic and asthenia) were observed in only 2% of the patients. At last follow-up, 81% of patients had discontinued TPO-RAs and maintained response, and 71% were alive. To our knowledge, this is the largest series analyzing the use of TPO-RAs after allo-SCT reported to date. Our results support the efficacy and safety in this new setting. Further prospective trials are needed to increase the level of evidence and to identify predictors of response.
dc.identifier.doi10.1016/j.bbmt.2019.05.023
dc.identifier.essn1523-6536
dc.identifier.pmid31152794
dc.identifier.unpaywallURLhttp://www.bbmt.org/article/S1083879119303349/pdf
dc.identifier.urihttp://hdl.handle.net/10668/14052
dc.issue.number9
dc.journal.titleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
dc.journal.titleabbreviationBiol Blood Marrow Transplant
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number1825-1831
dc.pubmedtypeClinical Trial
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAllogeneic stem cell transplantation
dc.subjectThrombocytopenia
dc.subjectThrombopoietin receptor agonists
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAllografts
dc.subject.meshBenzoates
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshFemale
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHumans
dc.subject.meshHydrazines
dc.subject.meshInfant
dc.subject.meshMale
dc.subject.meshPlatelet Count
dc.subject.meshPyrazoles
dc.subject.meshReceptors, Fc
dc.subject.meshReceptors, Thrombopoietin
dc.subject.meshRecombinant Fusion Proteins
dc.subject.meshRetrospective Studies
dc.subject.meshSeverity of Illness Index
dc.subject.meshSpain
dc.subject.meshThrombocytopenia
dc.subject.meshThrombopoietin
dc.titleThrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number25
dspace.entity.typePublication

Files